Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers

Pharmacogenetics

Volumn 12, Issue 7, 2002, Pages 571-580

  Kirchheiner, Julia ^a   Meineke, Ingolf ^a   Müller, Gunnar ^a   Roots, Ivar ^a   Brockmöller, Jürgen ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Antidepressant; CYP2C19; CYP2C9; CYP2D6; Doxepin; Pharmacogenetics

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DOXEPIN; NORDOXEPIN;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG TRANSFORMATION; FEMALE; FIRST PASS EFFECT; GENETIC POLYMORPHISM; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; STEREOCHEMISTRY;

ADULT; AGED; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; BODY MASS INDEX; CYTOCHROME P-450 CYP2D6; DOXEPIN; GENOTYPE; HUMANS; MIDDLE AGED; MIXED FUNCTION OXYGENASES; REFERENCE VALUES; SUBSTRATE SPECIFICITY;

EID: 0036797601     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200210000-00010     Document Type: Article

References (37)

1. Pinder RM, Brogden RN, Speight TM, Avery GS. Doxepin up-to-date: a review of its pharmacological properties and therapeutic efficacy with particular reference to depression. Drugs 1977; 13:161-218.
2. Bogaert MG, Rosseel MT, Deberdt R, Vranckx C. Plasma levels of the cis- and trans-isomers of doxepin and desmethyldoxepin after administration of doxepin to patients. Arzneimittelforschung 1981; 31:113-115.
3. Hrdina PD, Bakish D, Swenson S, Lapierre YD. Cis- and trans-isomers of doxepin and desmethyldoxepin in the plasma of depressed patients treated with doxepin. Ther Drug Monit 1990; 12:129-133.
4. Deuschle M, Härtter S, Hiemke C, Standhardt H, Heuser I. Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients. Psychopharmacology (Berl) 1997; 131:19-22.
5. Adamczyk M, Fishpaugh JR, Harrington C. Quantitative determination of E- and Z-doxepin and E- and Z-desmethyldoxepin by high-performance liquid chromatography. Ther Drug Monit 1995; 17:371-376.
6. Midha KK, Hubbard JW, McKay G, Hawes EM, Korchinski ED, Gurnsey T, et al. Stereoselective pharmacokinetics of doxepin isomers. Eur J Clin Pharmacol 1992; 42:539-544.
7. Schaumann W, Ribbentrop A. Interference of the central anticholinergic effect in experimental animal tests of potential antidepressives. Arzneimittelforschung 1966; 16:646-649.
8. Ribbentrop A, Schaumann W. Pharmacologic studies of doxepin, an antidepressive agent with centrally anticholinergic and sedative effects. Arzneimittelforschung 1965; 15:863-868.
9. Otsuki I, Ishikawa J, Sakai M, Shimabara K, Momiyama T. Comparison of the pharmacological activities of doxepin hydrochloride with those of its geometric isomers. Pharmacometrics (Tokyo) 1972; 6:973-984.
10. Faulkner RD, Pitts WM, Lee CS, Lewis WA, Fann WE. Multiple-dose doxepin kinetics in depressed patients. Clin Pharmacol Ther 1983; 34:509-515.
11. Ward NG, Bloom VL, Wilson L, Raskind M, Raisys VA. Doxepin plasma levels and therapeutic response in depression: preliminary findings. J Clin Psychopharmacol 1982; 2:126-128.
12. Leucht S, Steimer W, Kreuz S, Abraham D, Orsulak PJ, Kissling W. Doxepin plasma concentrations: is there really a therapeutic range? J Clin Psychopharmacol 2001; 21:432-439.
13. Shu YZ, Hubbard JW, Cooper JK, McKay G, Korchinski ED, Kumar R, et al. The identification of urinary metabolites of doxepin in patients. Drug Metab Dispos 1990; 18:735-741.
14. Haritos V, Ghabrial H, Ahokas J, Ching M. Role of cytochrome P450 2D6 (CYP2D6) in the stereospecific metabolism of E- and Z-doxepin. Pharmacogenetics 2000; 10:591-603.
15. Luo H, Hawes EM, McKay G, Korchinski ED, Midha KK. The quaternary ammonium-linked glucuronide of doxepin: a major metabolite in depressed patients treated with doxepin. Drug Metab Dispos 1991; 19:722-724.
16. Ereshefsky L, Tran-Johnson T, Davis CM, LeRoy A. Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine-new data and review. Clin Chem 1988; 34:863-880.
17. Härtter S, Tybring G, Friedberg T, Weigmann H, Hiemke C. The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharma Res 2002; 19:1035-1038.
18. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998; 38:112-121.
19. Baumann P, Jonzier Perey M, Koeb L, Küpfer A, Tinguely D, Schopf J. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin. Int Clin Psychopharmacol 1986; 1:102-112.
20. Nielsen KK, Brøsen K, Hansen MG, Gram LF. Single-dose kinetics of clomipramine: relationship to the sparteine and S-mephenytoin oxidation polymorphisms. Clin Pharmacol Ther 1994; 55:518-527.
21. Skjelbo E, Brøsen K, Hallas J, Gram LF. The mephenytoin oxidation polymorphism is partially responsible for the N-demethylation of imipramine. Clin Pharmacol Ther 1991; 49:18-23.
22. Morinobu S, Tanaka T, Kawakatsu S, Totsuka S, Koyama E, Chiba K, et al. Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry Clin Neurosci 1997; 51:253-257.
23. Eap CB, Bender S, Gastpar M, Fischer W, Haarmann C, Powell K, et al. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. Ther Drug Monit 2000; 22:209-214.
24. Koyama E, Tanaka T, Chiba K, Kawakatsu S, Morinobu S, Totsuka S, et al. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients. J Clin Psychopharmacol 1996; 16:286-293.
25. Burrows GD, Davies B, Norman T, Maguire K, Scoggins BA. Should plasma level monitoring of tricyclic antidepressants be introduced in clinical practice? Commun Psychopharmacol 1978; 2:393-408.
26. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996; 6:341-349.
27. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994; 269:15419-15422.
28. Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 1997; 60:284-295.
29. Meyer-Barner M, Meineke I, Schreeb KH, Gleiter CH. Pharmacokinetics of doxepin and desmethyldoxepin - an evaluation with the population approach. Eur J Clin Pharmacol 2002; 58:253-257.
30. Beal S, Sheiner L. NONMEM Users Guides., ed. U.o.C. NONMEM Project group. 1992, San Francisco.
31. Kirchheiner J, Brøsen K, Dahl ML, Gram LF, Kasper S, Roots I, et al. CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 2001; 104:173-192.
32. Ghabrial H, Prakash C, Tacke UG, Blair IA, Wilkinson GR. Geometric isomerization of doxepin during its N-demethylation in humans. Drug Metab Dispos 1991; 19:596-599.
33. Linder MW, Keck PE, Jr. Standards of laboratory practice: antidepressant drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998; 44:1073-1084.
34. Orsulak PJ. Therapeutic monitoring of antidepressant drugs: guidelines updated. Ther Drug Monit 1989; 11:497-507.
35. Risch SC, Kalin NH, Janowsky DS, Huey LY. Indications and guidelines for plasma tricyclic antidepressant concentration monitoring. J Clin Psychopharmacol 1981; 1:59-63.
36. Rao ML, Deister A, Laux G, Staberock U, Hoflich G, Möller HJ. Low serum levels of tricyclic antidepressants in amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with non-response. Pharmacopsychiatry 1996; 29:97-102.
37. Van Brunt N. The clinical utility of tricyclic antidepressant blood levels: a review of the literature. Ther Drug Monit 1983; 5:1-10.